Government Briefs

The current round of appropriations hearings in Congress graphically illustrates the different politicalforces that shape the NIH and NSF budgets. NSF officials, grilled by new subcommittee chairman Rep. Bob Traxler (D-Mich.),were asked to submit an analysis of where they would cut if the foundation’s proposed $262 million increase (amounting to 14%) were to be trimmed-by $50 million, $100 million, or $200 million. Traxler said that it’s highly unlikely that his panel, which also fun

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The current round of appropriations hearings in Congress graphically illustrates the different politicalforces that shape the NIH and NSF budgets. NSF officials, grilled by new subcommittee chairman Rep. Bob Traxler (D-Mich.),were asked to submit an analysis of where they would cut if the foundation’s proposed $262 million increase (amounting to 14%) were to be trimmed-by $50 million, $100 million, or $200 million. Traxler said that it’s highly unlikely that his panel, which also funds NASA, EPA, housing and the VA, will receive the additional $7 billion it needs to meet the administration’s proposed 1990 budget requests for those agencies, and he pressed NSF director Erich Bloch to set priorities. One week later, before veteransubcommittee chairman Rep. William Natcher (0-Ky.), NIH director James Wyngaarden was asked tc provide the panel with a description of how he would allocate $500 million more, in increments of $100 million, than the $233 million increase ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies